Earnings beat, guidance raised: our AI-picked pharma stock is up 23.96%

U.S. equities have faced renewed pressure from technology stocks this week as concerns over AI spending and returns weigh on investor sentiment. The VIX has climbed above 21, while major indexes have moved in different directions, reflecting a market increasingly divided over the outlook for technology and the broader economy.

Against that backdrop, one specialty pharmaceutical name on our AI models’ list has gained +23.96% since it was picked on September 1, 2026. The rally accelerated after the company reported a Q3 earnings beat and raised its full-year guidance on October 28, with shares surging 28.76% in the following session. InvestingPro members, who had this high-conviction pick on their November list for less than $8 a month, were already positioned before that session - and the run isn’t confined to one name.

Other recent wins on the AI list

Missed those picks? Here’s the good news: November’s list is ready - become a member to see it.

The pick: Bausch Health (NYSE: BHC)

The models flagged a stock priced as though the underlying pharmaceutical business had no path forward - deep undervaluation relative to its cash generation, with earnings growth that the market had not yet begun to price in.

What drove the move

That deep undervaluation was what the models saw before the catalyst arrived, and on October 29 the catalyst arrived. Bausch Health reported a Q3 2026 earnings beat and raised its full-year guidance, sending shares up 29% in a single session. That catalyst compressed the bulk of the +23.96% since-pick gain into a single week - and it arrived on top of balance sheet actions that further strengthened the thesis.

What members captured - and what the models saw first

Members who held BHC into October 29 captured the 29% single-session move - here’s what the models saw that put them there. As of this month’s review, three pillars keep that conviction intact.

The Fair Value gap of +48.3% suggests the market’s re-rating is still partial. With net debt of $18 billion the balance sheet carries real risk, but the direction of travel - notes retired, buyback authorized - is unambiguous.

A track record built on getting there first

The pick does not stand alone inside the strategy. Bausch Health belongs to the Healthcare Heroes strategy, which has returned +60.52% since its launch in August 2025, outpacing the S&P 500 Health Care index by +18.54 percentage points over the same period. That lead reflects a consistent pattern of high-conviction picks placed before the larger moves arrived:

How Investing.com’s AI-Powered Stock Picker Works

At the beginning of each month, our proprietary AI system evaluates thousands of global equities using a complex blend of historical data, valuation signals, and forward-looking growth metrics.

By processing more than 15 years of financial data across more than 150 quantitative models, the engine identifies up to 20 high-conviction stocks per strategy based on their projected medium-term upside potential.

Every month, these strategies undergo a strict rebalancing process. New opportunities are added, strong performers are retained, and stocks that no longer meet the criteria are removed.

To consistently track performance, each strategy utilises equal weighting across all selected stocks. While investors are free to adjust their own allocations, this structure provides a transparent benchmark for evaluating overall model performance.

The goal is to keep capital positioned in the companies showing the strongest combination of momentum, valuation, and business performance.

Still not a member? Then here’s your chance to get the full list of picks NOW:

*Live performance is recorded since our official launch of the Healthcare Heroes strategy in August 2025.

Subscription prices mentioned in articles are accurate at the time of publication. We regularly test different offers for our members, which may vary by region.

Past performance does not guarantee future results. Prices are accurate at the time of publication and may vary by region.